Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study

PURPOSE: Pembrolizumab monotherapy has demonstrated durable antitumor activity in advanced programmed death ligand 1 (PD-L1)–expressing non‒small-cell lung cancer (NSCLC). We report 5-year outcomes from the phase Ib KEYNOTE-001 study. These data provide the longest efficacy and safety follow-up for...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:J Clin Oncol
Main Authors: Garon, Edward B., Hellmann, Matthew D., Rizvi, Naiyer A., Carcereny, Enric, Leighl, Natasha B., Ahn, Myung-Ju, Eder, Joseph Paul, Balmanoukian, Ani S., Aggarwal, Charu, Horn, Leora, Patnaik, Amita, Gubens, Matthew, Ramalingam, Suresh S., Felip, Enriqueta, Goldman, Jonathan W., Scalzo, Cathie, Jensen, Erin, Kush, Debra A., Hui, Rina
Format: Artigo
Jezik:Inglês
Izdano: American Society of Clinical Oncology 2019
Teme:
RAPID COMMUNICATION
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC6768611/
https://ncbi.nlm.nih.gov/pubmed/31154919
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.19.00934
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki